Members of the Solid Biosciences team joined PPMD for a community webinar to review initial positive data from the INSPIRE DUCHENNE study of SGT-003, a next-generation microdystrophin gene therapy candidate. The Solid team provided a current update on the study, including microdystrophin expression and biomarker results from participants who have reached the Day 90 timepoint, as well as a safety update from the first six participants dosed. In addition, Solid outlined plans for continued dosing in the expanded phase 1/2 study.
Disclaimer: This webinar program is intended solely to provide information to the public. The views and opinions expressed as part of this webinar program do not necessarily state or reflect those of Parent Project Muscular Dystrophy (PPMD).